Gossamer Bio Inc.

0.99
-0.00 (-0.43%)
At close: Apr 02, 2025, 3:59 PM
0.98
-1.31%
After-hours: Apr 02, 2025, 06:15 PM EDT
-0.43%
Bid 0.98
Market Cap 225.63M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -0.25
PE Ratio (ttm) -3.97
Forward PE -1.3
Analyst Buy
Ask 1.03
Volume 1,524,471
Avg. Volume (20D) 1,480,971
Open 0.98
Previous Close 0.99
Day's Range 0.95 - 1.01
52-Week Range 0.50 - 1.55
Beta 1.86

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 144
Stock Exchange NASDAQ
Ticker Symbol GOSS
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 755.99% from the latest price.

Stock Forecasts

Next Earnings Release

Gossamer Bio Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
+22.26%
Gossamer Bio shares are trading higher after Oppen... Unlock content with Pro Subscription
9 months ago
+0.02%
Gossamer Bio shares are trading higher after competitor Aerovate Therapeutics reported topline results from the Phase 2b portion of IMPAHCT trial of AV-101 for pulmonary arterial hypertension.